Rznomics' RNA Drug for Liver Cancer Earns Key FDA Fast-Track Status

SEOUL, South Korea – May 08, 2026 – In a significant boost for liver cancer patients, the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RZ-001, a novel RNA-based gene therapy developed by South Korean biopharmaceutical firm Rznomics. The designation, announced today, aims to accelerate the development of what could be a groundbreaking treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer.

The RMAT status places RZ-001 on an expedited regulatory pathway, a decision based on promising interim data from an ongoing Phase 1b/2a clinical trial. This move signals the FDA's recognition of the drug's potential to address the high unmet medical needs of a patient population with limited effective treatment options.

A New Approach to Editing Cancer

At the heart of this development is Rznomics' proprietary trans-splicing ribozyme technology, a sophisticated form of RNA editing that represents a new frontier in oncology. Unlike conventional therapies that inhibit or destroy cancer cells from the outside, RZ-001 is designed to reprogram cancer cells from within.

The therapy targets a specific RNA molecule called human telomerase reverse transcriptase (hTERT), which is overexpressed in the vast majority of cancer cells and is crucial for their immortal proliferation. RZ-001 employs a dual-action mechanism: it first binds to and cleaves the hTERT RNA, effectively silencing its cancer-promoting function. In the same process, it splices in, or replaces the cleaved section with, the RNA sequence for a therapeutic "suicide gene"—herpes simplex virus thymidine kinase (HSVtk). This elegantly transforms the cancer cell into a factory for its own destruction, as the newly expressed enzyme makes the cell highly susceptible to an approved antiviral drug.

This innovative approach not only enhances tumor selectivity, as hTERT is primarily active in cancer cells, but also aims to improve safety by minimizing off-target effects on healthy tissue. This mechanism stands in stark contrast to the current standards of care, offering a completely new angle of attack against HCC.

The Power of an Accelerated Pathway

The RMAT designation is one of the FDA's most powerful tools for accelerating the delivery of transformative therapies to patients. Established under the 21st Century Cures Act, it is reserved for regenerative medicines, including cell and gene therapies, that show potential to treat serious or life-threatening conditions. The designation is highly selective; in 2022, the FDA granted only 14 of 30 requests, a success rate of just under 47%.

For Rznomics, this status unlocks significant benefits, including more frequent and intensive guidance from the FDA on clinical trial design and manufacturing. It also makes RZ-001 eligible for priority and rolling reviews, as well as pathways to accelerated approval. Accelerated approval can allow a drug to reach the market based on intermediate endpoints that are reasonably likely to predict clinical benefit, with full approval contingent on post-market confirmatory trials.

This is the third key FDA designation for RZ-001, following an Orphan Drug Designation in 2024 and Fast Track Designation in 2025, creating a powerful trifecta of regulatory support. "With the RMAT designation, we plan to accelerate our U.S. development and partnership initiatives by initiating formal discussions with the FDA regarding clinical trial design, Chemistry, Manufacturing, and Controls (CMC), and commercialization strategies," said Sung-woo Hong, Vice President of Rznomics.

Addressing a Critical Unmet Need

Hepatocellular carcinoma is a notoriously aggressive and deadly cancer, with a five-year survival rate below 20%. Despite recent advances, the treatment landscape is fraught with challenges. The current first-line standard of care for advanced HCC—combinations of immunotherapy agents—provides a durable response in only about 20% to 30% of patients. For those whose disease progresses, options are limited and often less effective.

This is the context in which RZ-001's early clinical results, presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, have generated excitement. The Phase 1b/2a trial evaluated RZ-001 in patients with advanced HCC. The interim data revealed an objective response rate (ORR) of 38.5% and, more strikingly, a 61.5% ORR when measured by mRECIST criteria, a specialized tool for HCC that assesses tumor viability. Perhaps most encouragingly, 23% of patients achieved a complete response, meaning all signs of their cancer disappeared. Critically, the therapy demonstrated a favorable safety profile, with no Grade 3 or higher adverse events attributed directly to RZ-001.

Rznomics' Strategic Ascent

The RMAT designation is a major clinical and regulatory victory for Rznomics, a company that has been on a rapid upward trajectory. Since listing on the KOSDAQ market in December 2025, the company's market capitalization has surged, reflecting investor confidence in its technology.

This confidence is further bolstered by a major strategic collaboration signed with global pharmaceutical giant Eli Lilly in May 2025. While that deal, potentially worth over $1.3 billion, is focused on developing an RNA-editing therapeutic for sensorineural hearing loss, it serves as a powerful external validation of Rznomics' core trans-splicing ribozyme platform. It demonstrates the technology's potential breadth and applicability beyond oncology.

Seong-Wook Lee, CEO of Rznomics, framed the latest news as a pivotal moment. "Receiving RMAT designation for RZ-001 is a profound validation of the innovation and competitiveness of our RNA editing platform by the FDA," he stated. "We will concentrate our resources on global development and commercialization to provide a breakthrough therapeutic option in the field of HCC, where unmet medical needs remain exceptionally high."

With a clear regulatory path forward and compelling clinical data in hand, Rznomics is now positioned to accelerate its efforts to bring this novel RNA therapy to liver cancer patients who are desperately awaiting new hope.